Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels

The sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin is increasingly used in the treatment of diabetes and heart failure. Dapagliflozin has been associated with reduced incidence of atrial fibrillation (AF) in clinical trials. We hypothesized that the favorable antiarrhythmic outcome...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Müller, Mara Elena (VerfasserIn) , Petersenn, Finn (VerfasserIn) , Hackbarth, Juline (VerfasserIn) , Pfeiffer, Julia (VerfasserIn) , Gampp, Heike (VerfasserIn) , Frey, Norbert (VerfasserIn) , Lugenbiel, Patrick (VerfasserIn) , Thomas, Dierk (VerfasserIn) , Rahm, Ann-Kathrin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 23 May 2024
In: International journal of molecular sciences
Year: 2024, Jahrgang: 25, Heft: 11, Pages: 1-14
ISSN:1422-0067
DOI:10.3390/ijms25115701
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms25115701
Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/25/11/5701
Volltext
Verfasserangaben:Mara Elena Müller, Finn Petersenn, Juline Hackbarth, Julia Pfeiffer, Heike Gampp, Norbert Frey, Patrick Lugenbiel, Dierk Thomas and Ann-Kathrin Rahm

MARC

LEADER 00000caa a2200000 c 4500
001 1908958901
003 DE-627
005 20241220171145.0
007 cr uuu---uuuuu
008 241119s2024 xx |||||o 00| ||eng c
024 7 |a 10.3390/ijms25115701  |2 doi 
035 |a (DE-627)1908958901 
035 |a (DE-599)KXP1908958901 
035 |a (OCoLC)1475647354 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Müller, Mara Elena  |e VerfasserIn  |0 (DE-588)1264420137  |0 (DE-627)1813255040  |4 aut 
245 1 0 |a Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels  |c Mara Elena Müller, Finn Petersenn, Juline Hackbarth, Julia Pfeiffer, Heike Gampp, Norbert Frey, Patrick Lugenbiel, Dierk Thomas and Ann-Kathrin Rahm 
246 3 0 |a two 
264 1 |c 23 May 2024 
300 |b Illustrationen 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 19.11.2024 
520 |a The sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin is increasingly used in the treatment of diabetes and heart failure. Dapagliflozin has been associated with reduced incidence of atrial fibrillation (AF) in clinical trials. We hypothesized that the favorable antiarrhythmic outcome of dapagliflozin use may be caused in part by previously unrecognized effects on atrial repolarizing potassium (K+) channels. This study was designed to assess direct pharmacological effects of dapagliflozin on cloned ion channels Kv11.1, Kv1.5, Kv4.3, Kir2.1, K2P2.1, K2P3.1, and K2P17.1, contributing to IKur, Ito, IKr, IK1, and IK2P K+ currents. Human channels coded by KCNH2, KCNA5, KCND3, KCNJ2, KCNK2, KCNK3, and KCNK17 were heterologously expressed in Xenopus laevis oocytes, and currents were recorded using the voltage clamp technique. Dapagliflozin (100 µM) reduced Kv11.1 and Kv1.5 currents, whereas Kir2.1, K2P2.1, and K2P17.1 currents were enhanced. The drug did not significantly affect peak current amplitudes of Kv4.3 or K2P3.1 K+ channels. Biophysical characterization did not reveal significant effects of dapagliflozin on current-voltage relationships of study channels. In conclusion, dapagliflozin exhibits direct functional interactions with human atrial K+ channels underlying IKur, IKr, IK1, and IK2P currents. Substantial activation of K2P2.1 and K2P17.1 currents could contribute to the beneficial antiarrhythmic outcome associated with the drug. Indirect or chronic effects remain to be investigated in vivo. 
650 4 |a arrhythmia 
650 4 |a dapagliflozin 
650 4 |a ion channel 
650 4 |a K+ channel 
650 4 |a repolarization 
650 4 |a sodium-glucose co-transporter-2 (SGLT2) inhibitor 
700 1 |a Petersenn, Finn  |e VerfasserIn  |0 (DE-588)1348716088  |0 (DE-627)190896202X  |4 aut 
700 1 |a Hackbarth, Juline  |e VerfasserIn  |4 aut 
700 1 |a Pfeiffer, Julia  |e VerfasserIn  |4 aut 
700 1 |a Gampp, Heike  |d 1998-  |e VerfasserIn  |0 (DE-588)1279224878  |0 (DE-627)1832502678  |4 aut 
700 1 |a Frey, Norbert  |e VerfasserIn  |0 (DE-588)141244976  |0 (DE-627)625824075  |0 (DE-576)322969514  |4 aut 
700 1 |a Lugenbiel, Patrick  |d 1982-  |e VerfasserIn  |0 (DE-588)137855710  |0 (DE-627)696120062  |0 (DE-576)305349414  |4 aut 
700 1 |a Thomas, Dierk  |d 1974-  |e VerfasserIn  |0 (DE-588)123896258  |0 (DE-627)706465601  |0 (DE-576)29393164X  |4 aut 
700 1 |a Rahm, Ann-Kathrin  |d 1988-  |e VerfasserIn  |0 (DE-588)1054163049  |0 (DE-627)791115690  |0 (DE-576)410045217  |4 aut 
773 0 8 |i Enthalten in  |t International journal of molecular sciences  |d Basel : Molecular Diversity Preservation International, 2000  |g 25(2024), 11, Artikel-ID 5701, Seite 1-14  |h Online-Ressource  |w (DE-627)316340715  |w (DE-600)2019364-6  |w (DE-576)281194653  |x 1422-0067  |7 nnas  |a Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels 
773 1 8 |g volume:25  |g year:2024  |g number:11  |g elocationid:5701  |g pages:1-14  |g extent:14  |a Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels 
856 4 0 |u https://doi.org/10.3390/ijms25115701  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/1422-0067/25/11/5701  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20241119 
993 |a Article 
994 |a 2024 
998 |g 1054163049  |a Rahm, Ann-Kathrin  |m 1054163049:Rahm, Ann-Kathrin  |d 910000  |d 910100  |e 910000PR1054163049  |e 910100PR1054163049  |k 0/910000/  |k 1/910000/910100/  |p 9  |y j 
998 |g 123896258  |a Thomas, Dierk  |m 123896258:Thomas, Dierk  |d 910000  |d 910100  |d 50000  |e 910000PT123896258  |e 910100PT123896258  |e 50000PT123896258  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 8 
998 |g 137855710  |a Lugenbiel, Patrick  |m 137855710:Lugenbiel, Patrick  |d 910000  |d 910100  |d 50000  |e 910000PL137855710  |e 910100PL137855710  |e 50000PL137855710  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 7 
998 |g 141244976  |a Frey, Norbert  |m 141244976:Frey, Norbert  |d 910000  |d 910100  |e 910000PF141244976  |e 910100PF141244976  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 1279224878  |a Gampp, Heike  |m 1279224878:Gampp, Heike  |d 50000  |e 50000PG1279224878  |k 0/50000/  |p 5 
998 |g 1348716088  |a Petersenn, Finn  |m 1348716088:Petersenn, Finn  |d 50000  |e 50000PP1348716088  |k 0/50000/  |p 2 
998 |g 1264420137  |a Müller, Mara Elena  |m 1264420137:Müller, Mara Elena  |d 910000  |d 910100  |e 910000PM1264420137  |e 910100PM1264420137  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1908958901  |e 461631490X 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1908958901","person":[{"given":"Mara Elena","display":"Müller, Mara Elena","family":"Müller","role":"aut"},{"role":"aut","family":"Petersenn","display":"Petersenn, Finn","given":"Finn"},{"display":"Hackbarth, Juline","given":"Juline","family":"Hackbarth","role":"aut"},{"family":"Pfeiffer","role":"aut","display":"Pfeiffer, Julia","given":"Julia"},{"family":"Gampp","role":"aut","display":"Gampp, Heike","given":"Heike"},{"role":"aut","family":"Frey","display":"Frey, Norbert","given":"Norbert"},{"family":"Lugenbiel","role":"aut","given":"Patrick","display":"Lugenbiel, Patrick"},{"display":"Thomas, Dierk","given":"Dierk","family":"Thomas","role":"aut"},{"given":"Ann-Kathrin","display":"Rahm, Ann-Kathrin","role":"aut","family":"Rahm"}],"note":["Gesehen am 19.11.2024"],"name":{"displayForm":["Mara Elena Müller, Finn Petersenn, Juline Hackbarth, Julia Pfeiffer, Heike Gampp, Norbert Frey, Patrick Lugenbiel, Dierk Thomas and Ann-Kathrin Rahm"]},"language":["eng"],"relHost":[{"disp":"Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channelsInternational journal of molecular sciences","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"IJMS"}],"language":["eng"],"part":{"year":"2024","volume":"25","text":"25(2024), 11, Artikel-ID 5701, Seite 1-14","extent":"14","pages":"1-14","issue":"11"},"pubHistory":["1.2000 -"],"note":["Gesehen am 17.09.20"],"title":[{"title_sort":"International journal of molecular sciences","title":"International journal of molecular sciences"}],"id":{"zdb":["2019364-6"],"eki":["316340715"],"issn":["1422-0067","1661-6596"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"2000","publisherPlace":"Basel","publisher":"Molecular Diversity Preservation International","dateIssuedDisp":"2000-"}],"recId":"316340715"}],"origin":[{"dateIssuedDisp":"23 May 2024","dateIssuedKey":"2024"}],"title":[{"title":"Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels","title_sort":"Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"14 S.","noteIll":"Illustrationen"}],"id":{"doi":["10.3390/ijms25115701"],"eki":["1908958901"]}} 
SRT |a MUELLERMARELECTROPHY2320